161Tb-LNC1011

N/A

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug Name161Tb-LNC1011
Drug Alias Name161Tb-LNC1011
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug ConjugatesSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC) +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYantai Lannacheng Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMianyang Central HospitalPeking Union Medical College Hospital
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A